Clinical Trial

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 25, 2024 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to determine the efficacy and safety of Hyperthermic Intravesical Chemotherapy (HIVEC) with Gemcitabine (GEM) after Transurethral Resection of Bladder Tumors (TURBT) in the treatment of medium or high-risk group Non-Muscle-Invasive Bladder Cancer (NMIBC).
Trial Details
NCT Number NCT06327932
Lead Sponsor Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Conditions Non-Muscle-Invasive Bladder Cancer
Enrollment 320 participants
Start Date 2024-04-01
Primary Completion 2026-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-03-25